Comparison of 68Ga-DOTA-NaI3-Octreotide/tyr3-octreotate positron emission tomography/computed tomography and contrast-enhanced computed tomography in localization of tumors in multiple endocrine neoplasia 1 syndrome

scientific article published on 29 January 2020

Comparison of 68Ga-DOTA-NaI3-Octreotide/tyr3-octreotate positron emission tomography/computed tomography and contrast-enhanced computed tomography in localization of tumors in multiple endocrine neoplasia 1 syndrome is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.4103/WJNM.WJNM_24_19
P932PMC publication ID7478292
P698PubMed publication ID32939195

P2093author name stringNalini S Shah
Tushar R Bandgar
Hina Shah
Gaurav Malhotra
Vikram R Lele
Priya Hira
Vijaya Sarathi
Anurag Lila
Swati Jadhav
Manjunath R Goroshi
Virendra A Patil
P2860cites workImpact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia.Q51320250
Preoperative assessment of the pancreas in multiple endocrine neoplasia type 1.Q51356001
Multiple endocrine neoplasia type 1 syndrome: single centre experience from western India.Q52984755
Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).Q52992707
¹⁸F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study.Q53058863
Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor.Q53059695
68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol.Q53083280
Thymic Neuroendocrine Neoplasms: Biological Behaviour and Therapy.Q53637052
Somatostatin Receptor Imaging with68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in InterpretationQ57758753
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromesQ24603675
Radiological surveillance in multiple endocrine neoplasia type 1: a double-edged sword?Q33656493
Guidelines for diagnosis and therapy of MEN type 1 and type 2.Q34104591
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).Q34283436
A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003.Q34650336
Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1.Q35891227
Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysisQ37986605
Neuroendocrine tumours: the role of imaging for diagnosis and therapyQ38169928
The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.Q38243866
Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and stagingQ38772470
Focused parathyroidectomy without intraoperative parathormone testing is safe after pre-operative localization with 18F-Fluorocholine PET/CT.Q38989715
Management impact: effects on quality of life and prognosis in MEN1.Q39451392
Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.Q40051095
Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?Q40182879
Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversiesQ43066318
Percentage arterial enhancement: An objective index for accurate identification of parathyroid adenoma/hyperplasia in primary hyperparathyroidism.Q48213734
P275copyright licenseCreative Commons Attribution-NonCommercial-NoDerivs 4.0 InternationalQ24082749
P6216copyright statuscopyrightedQ50423863
P433issue2
P921main subjectcomputed tomographyQ32566
multiple endocrine neoplasiaQ1553018
P304page(s)99-105
P577publication date2020-01-29
P1433published inWorld Journal of Nuclear MedicineQ15817346
P1476titleComparison of 68Ga-DOTA-NaI3-Octreotide/tyr3-octreotate positron emission tomography/computed tomography and contrast-enhanced computed tomography in localization of tumors in multiple endocrine neoplasia 1 syndrome
P478volume19

Search more.